Expertise in

conditions

Dr. Douglas Weckstein

Hematology

Office

200 Technology Dr,

Hooksett, NH

Clinical Trials:Currently Recruiting for 5 Trials

Expertise in

conditions

Office

200 Technology Dr,

Hooksett, NH

Overview

Douglas Weckstein is a Hematologist in Hooksett, New Hampshire. Dr. Weckstein is highly rated in 31 conditions, according to our data. His top areas of expertise are Lung Cancer, Paget Disease of the Breast, Breast Cancer, Inflammatory Breast Cancer, and Prostatectomy.

His clinical research consists of co-authoring 16 peer reviewed articles and participating in 69 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology

Licenses

Internal Medicine in NH

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Anthem BCBS

Blue Cross Blue Shield

BMC HealthNet

HMO
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE SNP

CareFirst

Cigna

Commonwealth Care Alliance

MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN

Health Care Services Corporation

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

Humana

HMO
INDEMNITY
POS
PPO

Independent Health

Managed Medicaid

OTHER MANAGED MEDICAID

Martin's Point Generations

MEDICARE MAPD
OTHER MEDICARE

Medicaid

OTHER MEDICAID
STATE MEDICAID

NH Healthy Families

EPO
MANAGED MEDICAID PLAN

Tufts

UnitedHealthcare

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

View 12 Less Insurance Carriers -

Locations

Office
200 Technology Dr, Hooksett, NH 03106

Call: 800-339-6484

Other Locations

Office
40 Buttrick Rd # B, Londonderry, NH 03053

Call: 603-552-9100

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

67 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)

Enrollment Status: Recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Other, Biological

Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium

Study Phase: Phase 3

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Enrollment Status: Recruiting

Publish Date: January 22, 2026

Intervention Type: Drug

Study Drugs: Crizotinib, Palbociclib, Sunitinib, Temsirolimus, Trastuzumab and Pertuzumab, Vemurafenib and Cobimetinib, Regorafenib, Olaparib, Pembrolizumab, Nivolumab and Ipilimumab, Abemaciclib, Afatinib, Talazoparib, Atezolizumab and PHESGO, Atezolizumab and Talazoparib, Entrectinib, Larotrectinib, Tucatinib plus Trastuzumab Subcutaneous (SC)

Study Phase: Phase 2

Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy

Enrollment Status: Recruiting

Publish Date: January 14, 2026

Intervention Type: Other, Procedure, Drug, Radiation

Study Drugs: Abiraterone acetate, Apalutamide, Hormone therapy, Prednisone

Study Phase: Phase 3

TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

Enrollment Status: Recruiting

Publish Date: January 13, 2026

Intervention Type: Radiation, Other

Study Phase: Phase 3

LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)

Enrollment Status: Recruiting

Publish Date: December 05, 2025

Intervention Type: Drug

Study Drug: Screening Platform

Study Phase: Phase 2/Phase 3

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Biological, Procedure

Study Drug: Pembrolizumab

Study Phase: Phase 3

MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients With Metastatic Urothelial Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Procedure, Drug

Study Drugs: Avelumab, Cabozantinib S-malate

Study Phase: Phase 3

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Radiation, Procedure, Biological

Study Drug: Pembrolizumab

Study Phase: Phase 3

A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Biological, Drug

Study Drugs: Carboplatin, Nivolumab, Paclitaxel

Study Phase: Phase 3

Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Drug

Study Drug: Erlotinib Hydrochloride

Study Phase: Phase 3

A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Procedure, Drug, Biological

Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax

Study Phase: Phase 3

Molecular Analysis for Therapy Choice (MATCH)

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Other, Biological

Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib

Study Phase: Phase 2

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Biological, Other

Study Drug: Nivolumab

Study Phase: Phase 3

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Drug, Biological

Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium

Study Phase: Phase 3

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Procedure, Biological, Drug

Study Phase: Not Applicable

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 10, 2026

Intervention Type: Drug, Other

Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate

Study Phase: Phase 3

CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 05, 2026

Intervention Type: Other, Drug

Study Drugs: Enzalutamide, Rucaparib Camsylate, Leuprolide Acetate, Goserelin Acetate, Degarelix

Study Phase: Phase 3

Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Enrollment Status: Active_not_recruiting

Publish Date: February 02, 2026

Intervention Type: Other, Procedure, Drug

Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin

Study Phase: Phase 3

A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)

Enrollment Status: Active_not_recruiting

Publish Date: February 02, 2026

Intervention Type: Drug, Biological, Other

Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax

Study Phase: Phase 3

A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers

Enrollment Status: Active_not_recruiting

Publish Date: January 28, 2026

Intervention Type: Other, Drug

Study Drug: Sinecatechins

Study Phase: Phase 2

Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS: A Phase III Prospective Randomized Trial

Enrollment Status: Active_not_recruiting

Publish Date: January 27, 2026

Intervention Type: Other

Study Phase: Not Applicable

A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)

Enrollment Status: Active_not_recruiting

Publish Date: January 26, 2026

Intervention Type: Other, Drug

Study Drugs: Darolutamide, Goserelin acetate, Leuprolide acetate, Triptorelin

Study Phase: Phase 3

(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response

Enrollment Status: Active_not_recruiting

Publish Date: January 26, 2026

Intervention Type: Procedure, Biological, Drug, Radiation

Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine

Study Phase: Phase 2

A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age

Enrollment Status: Active_not_recruiting

Publish Date: January 22, 2026

Intervention Type: Drug, Procedure

Study Drugs: Lenalidomide, Bortezomib, Dexamethasone

Study Phase: Phase 3

Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study

Enrollment Status: Active_not_recruiting

Publish Date: January 22, 2026

Intervention Type: Drug

Study Drugs: Fulvestrant, Anastrozole

Study Phase: Phase 3

A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)

Enrollment Status: Active_not_recruiting

Publish Date: January 14, 2026

Intervention Type: Other, Radiation, Drug

Study Drug: Apalutamide

Study Phase: Phase 2

Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)

Enrollment Status: Active_not_recruiting

Publish Date: January 14, 2026

Intervention Type: Drug, Procedure, Other, Radiation

Study Drugs: Abiraterone acetate, Apalutamide, Bicalutamide, Buserelin, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Prednisone, Triptorelin

Study Phase: Phase 3

A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer

Enrollment Status: Completed

Publish Date: December 31, 2025

Intervention Type: Drug

Study Drugs: TAK-700, Bicalutamide

Study Phase: Phase 3

A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

Enrollment Status: Completed

Publish Date: December 30, 2025

Intervention Type: Other, Procedure, Biological, Drug

Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab

Study Phase: Phase 3

Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)

Enrollment Status: Active_not_recruiting

Publish Date: December 22, 2025

Intervention Type: Other, Dietary supplement, Drug

Study Drugs: Bevacizumab, Oxaliplatin, Leucovorin calcium, Fluorouracil, Irinotecan hydrochloride, Irinotecan

Study Phase: Phase 3

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Enrollment Status: Active_not_recruiting

Publish Date: December 19, 2025

Intervention Type: Other, Drug

Study Drug: Crizotinib

Study Phase: Phase 3

A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)

Enrollment Status: Active_not_recruiting

Publish Date: December 05, 2025

Intervention Type: Drug

Study Drug: Sotorasib

Study Phase: Phase 2

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab

Enrollment Status: Active_not_recruiting

Publish Date: December 03, 2025

Intervention Type: Other, Drug, Radiation, Procedure

Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide

Study Phase: Phase 3

Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: November 28, 2025

Intervention Type: Drug, Biological, Other

Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate

Study Phase: Phase 2

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Enrollment Status: Active_not_recruiting

Publish Date: November 28, 2025

Intervention Type: Other, Drug

Study Drugs: Temozolomide, Veliparib

Study Phase: Phase 2/Phase 3

EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis

Enrollment Status: Active_not_recruiting

Publish Date: November 25, 2025

Intervention Type: Procedure, Drug, Biological

Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed

Study Phase: Phase 3

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Other, Procedure, Drug, Biological

Study Drugs: Cabozantinib, Ipilimumab, Nivolumab

Study Phase: Phase 3

A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Procedure, Drug, Biological

Study Drugs: Cabozantinib S-malate, Docetaxel, Gemcitabine Hydrochloride, Nab-paclitaxel, Nivolumab, Paclitaxel, Ramucirumab

Study Phase: Phase 2

The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib

Enrollment Status: Active_not_recruiting

Publish Date: October 29, 2025

Intervention Type: Other, Biological, Drug

Study Drugs: Trastuzumab Emtansine, Tucatinib

Study Phase: Phase 3

Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)

Enrollment Status: Active_not_recruiting

Publish Date: September 08, 2025

Intervention Type: Other, Drug

Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide

Study Phase: Phase 3

A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer

Enrollment Status: Terminated

Publish Date: July 17, 2025

Intervention Type: Other, Drug

Study Drug: Naloxegol

Study Phase: Phase 2

A Phase II Study of LOXO-292 in Patients With RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)

Enrollment Status: Active_not_recruiting

Publish Date: July 11, 2025

Intervention Type: Drug

Study Drug: Selpercatinib

Study Phase: Phase 2

Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)

Enrollment Status: Completed

Publish Date: July 03, 2025

Intervention Type: Drug, Biological

Study Drugs: Carboplatin, Cisplatin, Etoposide, Nivolumab

Study Phase: Phase 2

Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)

Enrollment Status: Active_not_recruiting

Publish Date: June 13, 2025

Intervention Type: Other, Drug

Study Drugs: Pembrolizumab, Pemetrexed, Carboplatin

Study Phase: Phase 2

A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)

Enrollment Status: Active_not_recruiting

Publish Date: May 21, 2025

Intervention Type: Other, Biological

Study Drugs: Ipilimumab, Nivolumab

Study Phase: Phase 3

A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)

Enrollment Status: Completed

Publish Date: May 21, 2025

Intervention Type: Drug

Study Drug: Rucaparib

Study Phase: Phase 2

A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy

Enrollment Status: Completed

Publish Date: May 18, 2025

Intervention Type: Drug

Study Drug: Apixaban

Study Phase: Phase 3

A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases

Enrollment Status: Active_not_recruiting

Publish Date: April 24, 2025

Intervention Type: Biological

Study Drug: Sacituzumab Govitecan

Study Phase: Phase 2

A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)

Enrollment Status: Active_not_recruiting

Publish Date: March 17, 2025

Intervention Type: Drug

Study Drugs: Trastuzumab, Paclitaxel, Trastuzumab emtansine

Study Phase: Phase 2

Phase III Placebo-Controlled Trial to Evaluate Dexamethasone Use for Everolimus-Induced Oral Stomatitis: Prevention Versus Early Treatment Approaches: MIST (My Individualized Stomatitis Treatment)

Enrollment Status: Terminated

Publish Date: January 29, 2025

Intervention Type: Other, Drug

Study Phase: Phase 3

View 45 Less Clinical Trials

16 Total Publications

Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 27, 2024

View All 16 Publications

Similar Doctors

Expertise in

conditions

Dr. David Kuter

Hematology

Expertise in

conditions

Dr. David Kuter

Hematology

Massachusetts General Hospital

55 Fruit St,

Boston, MA

(62.9 miles away)

617-724-4000

Languages Spoken:

English

See accepted insurances

Offers Telehealth

David Kuter is a Hematologist in Boston, Massachusetts. Dr. Kuter is highly rated in 42 conditions, according to our data. His top areas of expertise are Immune Thrombocytopenic Purpura (ITP), Adult Immune Thrombocytopenia, Thrombocytopenia, Autoimmune Hemolytic Anemia, and Splenectomy.

Expertise in

conditions

Dr. Steven Dubois

Hematology | Oncology

Expertise in

conditions

Dr. Steven Dubois

Hematology | Oncology

Dana-Farber Cancer Institute

450 Brookline Ave,

Boston, MA

(63.7 miles away)

877-442-3324

Languages Spoken:

English

See accepted insurances

Steven Dubois is a Hematologist and an Oncologist in Boston, Massachusetts. Dr. Dubois is highly rated in 11 conditions, according to our data. His top areas of expertise are Ewing Sarcoma, Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, and Osteosarcoma.

Expertise in

conditions

Dr. Corey Cutler

Hematology

Expertise in

conditions

Dr. Corey Cutler

Hematology

Dana-Farber Cancer Institute

450 Brookline Ave,

Boston, MA

(63.7 miles away)

877-442-3324

Languages Spoken:

English

See accepted insurances

Corey Cutler is a Hematologist in Boston, Massachusetts. Dr. Cutler is highly rated in 23 conditions, according to our data. His top areas of expertise are Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Graft.

VIEW MORE Hematologists

Frequently Asked Questions about Dr. Douglas Weckstein

How do I make an appointment with Dr. Douglas Weckstein?

You can book an appointment with Dr. Douglas Weckstein by calling their office at 800-339-6484. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Douglas Weckstein a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Douglas Weckstein is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Douglas Weckstein specialize in?

While Dr. Douglas Weckstein is a Hematology, they have specific expertise in Lung Cancer, Paget Disease of the Breast, and Breast Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Douglas Weckstein participate in research or clinical trials?

Yes. Dr. Douglas Weckstein has published 16 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Douglas Weckstein's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Douglas Weckstein accept my insurance?

Dr. Douglas Weckstein accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 800-339-6484 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Weckstein's expertise for a condition

ConditionClose